Mosanna Therapeutics secures multi-million dollar funding for clinical development of MOS-118 for the treatment of sleep apnea

Mosanna Therapeutics expands its seed round with million-dollar funding from investors including Supermoon Capital and HTGF for the development of MOS-118. The funding will enable the company to submit its IND application and investigate the mechanism of action and proof-of-concept in clinical trials.

Swiss biotech company Mosanna Therapeutics AG has expanded its seed financing round to include investors Supermoon Capital and High-Tech Gründerfonds (HTGF). The investors join lead investor Forty51 Ventures to complete the syndicate. Mosanna plans to file an IND application by the end of 2023 and will use the funding for manufacturing and regulatory activities in preparation for a clinical development program.

This additional funding is a testament to the significant clinical benefit the team sees for sleep apnea patients.

Jonathan Talbot, CEO Mosanna

About Metabolic Obstructive Sleep Apnea

Metabolic Obstructive Sleep Apnea is a form of sleep apnea caused by obstructive breathing during sleep and is common in patients with obesity and diabetes. The upper airway becomes blocked during sleep due to slack muscles or excessive tissue, resulting in impaired airflow. MOS patients experience repeated breathing cessations during sleep, which can lead to oxygen deprivation and potential health risks such as cardiovascular disease. Early diagnosis and treatment of MOS are therefore important to reduce the health impact.

We are absolutely confident that Mosanna will successfully develop MOS-118 and redefine the standard of care for sleep apnea.

Laura Pedroza, Investment Manager HTGF

About Forty51 Ventures

FORTY51 Ventures is a biotech company focused on venture creation and early-stage investments in European biotech companies. It was founded in April 2022 with headquarters in Basel, Switzerland. The VC invests in early-stage single agents or platforms that have a clear path to the clinic. A focus is on therapeutic areas such as CNS, oncology, immunology and inflammation, fibrotic disorders and optha.

About HTGF

High-Tech Gründerfonds (HTGF) is an investor in technology-driven startups. Since 2005, HTGF has launched three funds with a total investment volume of 895.5 million euros and has supported over 550 start-ups. The team of investment managers and start-up experts supports young companies in their development. HTGF focuses on start-ups in various high-tech sectors, such as software, media, Internet, hardware, automation, healthcare, chemicals and life sciences. HTGF's portfolio has already received over €2 billion from external investors in more than 1,400 follow-on financing rounds and over 100 companies have been successfully sold. HTGF is a public-private partnership and is supported by the German Federal Ministry for Economic Affairs and Energy and KfW Capital, among others.